{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=olaparib&page=9", "query": { "intervention": "olaparib", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 226, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=olaparib&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=olaparib&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:40:31.580Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02546661", "title": "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "AZD4547", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "AZD1775", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "AZD9150", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 117, "start_date": "2016-12-28", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 8, "location_summary": "Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546661" }, { "nct_id": "NCT05203445", "title": "A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-01-31", "completion_date": "2027-01", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05203445" }, { "nct_id": "NCT06580314", "title": "Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor", "FIGO Stage III Ovarian Cancer 2014", "FIGO Stage IV Ovarian Cancer 2014", "Ovarian Carcinoma", "Ovarian Carcinosarcoma", "Ovarian High Grade Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2025-03-12", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 676, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580314" }, { "nct_id": "NCT05240898", "title": "A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "RO7623066", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2021-08-26", "completion_date": "2025-11-26", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 15, "location_summary": "Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05240898" }, { "nct_id": "NCT04041128", "title": "PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "Lynparza", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 14, "start_date": "2019-07-23", "completion_date": "2021-06-15", "has_results": false, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041128" }, { "nct_id": "NCT04090567", "title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2020-07-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090567" }, { "nct_id": "NCT03079687", "title": "Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Olaparib tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-10-25", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 13, "location_summary": "Duarte, California • Newport Beach, California • Roseville, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT03079687" }, { "nct_id": "NCT02561832", "title": "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Anthracycline", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 15, "start_date": "2015-11-06", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2019-02-20", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 2, "location_summary": "New York, New York • Stony Brook, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02561832" }, { "nct_id": "NCT03205176", "title": "AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumors", "Lymphoma", "Ovarian Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "AZD5153", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 49, "start_date": "2017-06-30", "completion_date": "2021-04-08", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 3, "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03205176" }, { "nct_id": "NCT04711824", "title": "Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Brain Metastases, Adult" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Physicians Choice systemic chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Colette Shen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2022-03-09", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-18T09:40:31.580Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711824" } ] }